Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection

Journal of Controlled Release

Volumn 162, Issue 1, 2012, Pages 102-110

  Steinbach, Jill M ^a   Weller, Caroline E ^a   Booth, Carmen J ^b   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; HSV 2; Microbicide; Nanoparticle; siRNA

Indexed keywords

CONTROLLED RELEASE; HOST CELL PROTEIN; HOST CELLS; HSV-2; IN-VITRO; LETHAL DOSE; MICROBICIDE; MICROBICIDES; MOUSE MODELS; OPTIMAL FORMULATION; PLGA NANOPARTICLES; POLY(LACTIC-CO-GLYCOLIC ACID); POLYMER NANOPARTICLES; PROOF OF CONCEPT; SHORT INTERFERING RNA (SIRNA); SIRNA; SIRNA TREATMENT; VIRAL INFECTIONS;

DRUG DELIVERY; GENES; LOADING; NANOPARTICLES; RNA; TISSUE;

MAMMALS;

MESSENGER RNA; NANOPARTICLE; NECTIN 1; POLYGLACTIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENITAL TRACT INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY;

ANIMALS; CELL ADHESION MOLECULES; DRUG CARRIERS; FEMALE; GENETIC THERAPY; HELA CELLS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; LACTIC ACID; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYGLYCOLIC ACID; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84864704156     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.06.008     Document Type: Article

References (34)

1. L.C. Rohan, and A.B. Sassi Vaginal drug delivery systems for HIV prevention AAPS J. 11 1 2009 78 87
2. F. Xu, M.R. Sternberg, B.J. Kottiri, G.M. McQuillan, F.K. Lee, A.J. Nahmias, S.M. Berman, and L.E. Markowitz Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States JAMA 296 8 2006 964 973
3. K.J. Looker, G.P. Garnett, and G.P. Schmid An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection Bull. World Health Organ. 86 10 2008 805 812 A.
4. L. Corey, A. Wald, C.L. Celum, and T.C. Quinn The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics (1999) J. Acquir. Immune Defic. Syndr. 35 5 2004 435 445
5. L. Macmillan, G.O. Ifere, Q. He, J.U. Igietseme, K.L. Kellar, D.M. Okenu, and F.O. Eko A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes FEMS Immunol. Med. Microbiol. 49 1 2007 46 55
6. A.A. Tobian, and T.C. Quinn Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention Curr. Opin. HIV AIDS 4 4 2009 294 299
7. D.M. Koelle, and L. Corey Herpes simplex: insights on pathogenesis and possible vaccines Annu. Rev. Med. 59 2008 381 395
8. Will there be an HIV vaccine in the next 10 years? Nat. Med. 13 2007 518 519
9. G. Dasgupta, A.A. Chentoufi, A.B. Nesburn, S.L. Wechsler, and L. BenMohamed New concepts in herpes simplex virus vaccine development: notes from the battlefield Expert Rev. Vaccines 8 8 2009 1023 1035
10. J.A. Fernandez-Romero, C.J. Abraham, A. Rodriguez, L. Kizima, N. Jean-Pierre, R. Menon, O. Begay, S. Seidor, B.E. Ford, P.I. Gil, J. Peters, D. Katz, M. Robbiani, and T.M. Zydowsky Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge Antimicrob Agents Chemother 56 1 2012 358 368
11. J.C. Overall Jr., E.R. Kern, R.L. Schlitzer, S.B. Friedman, and L.A. Glasgow Genital herpesvirus hominis infection in mice. I. Development of an experimental model Infect. Immun. 11 3 1975 476 480
12. D. Palliser, D. Chowdhury, Q.Y. Wang, S.J. Lee, R.T. Bronson, D.M. Knipe, and J. Lieberman An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Nature 439 7072 2006 89 94
13. Y. Wu, F. Navarro, A. Lal, E. Basar, R.K. Pandey, M. Manoharan, Y. Feng, S.J. Lee, J. Lieberman, and D. Palliser Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene Cell Host Microbe 5 1 2009 84 94
14. C. Kaushic, A.A. Ashkar, L.A. Reid, and K.L. Rosenthal Progesterone increases susceptibility and decreases immune responses to genital herpes infection J. Virol. 77 8 2003 4558 4565
15. M.B. Parr, and E.L. Parr Intravaginal administration of herpes simplex virus type 2 to mice leads to infection of several neural and extraneural sites J. Neurovirol. 9 6 2003 594 602
16. K.C. Yim, C.J. Carroll, A. Tuyama, N. Cheshenko, M.J. Carlucci, D.D. Porter, G.A. Prince, and B.C. Herold The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies J. Virol. 79 23 2005 14632 14639
17. M.M. Linehan, S. Richman, C. Krummenacher, R.J. Eisenberg, G.H. Cohen, and A. Iwasaki In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa J. Virol. 78 5 2004 2530 2536
18. K.A. Woodrow, Y. Cu, C.J. Booth, J.K. Saucier-Sawyer, M.J. Wood, and W.M. Saltzman Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA Nat. Mater. 8 6 2009 526 533
19. A.E. Spang, P.J. Godowski, and D.M. Knipe Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein J. Virol. 45 1 1983 332 342
20. S.Y. Wu, H.I. Chang, M. Burgess, and N.A. McMillan Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system J. Control. Release 155 3 2011 418 426
21. Y. Zhang, P. Cristofaro, R. Silbermann, O. Pusch, D. Boden, T. Konkin, V. Hovanesian, P.R. Monfils, M. Resnick, S.F. Moss, and B. Ramratnam Engineering mucosal RNA interference in vivo Mol. Ther. 14 3 2006 336 342
22. L.A. Wheeler, R. Trifonova, V. Vrbanac, E. Basar, S. McKernan, Z. Xu, E. Seung, M. Deruaz, T. Dudek, J.I. Einarsson, L. Yang, T.M. Allen, A.D. Luster, A.M. Tager, D.M. Dykxhoorn, J. Lieberman, Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121(6) 2401-2412.
23. C.C. Conwell, F. Liu, and L. Huang Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors Mol. Ther. 16 2 2008 370 377
24. E. Khazanov, D. Simberg, and Y. Barenholz Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice J. Gene Med. 8 8 2006 998 1007
25. K.J. Whaley, J. Hanes, R. Shattock, R.A. Cone, and D.R. Friend Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines Antiviral research 88 Suppl 1 2010 S55 S66
26. R.W. Buckheit Jr., K.M. Watson, K.M. Morrow, and A.S. Ham Development of topical microbicides to prevent the sexual transmission of HIV Antiviral Res. 85 1 2010 142 158
27. B. Cutler, and J. Justman Vaginal microbicides and the prevention of HIV transmission Lancet Infect. Dis. 8 11 2008 685 697
28. M.M. Lederman, R.E. Offord, and O. Hartley Microbicides and other topical strategies to prevent vaginal transmission of HIV Nat. Rev. Immunol. 6 5 2006 371 382
29. S.K. Eszterhas, N.O. Ilonzo, J.E. Crozier, S. Celaj, and A.L. Howell Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants Infect. Dis. Rep. 3 11 2011 52 61
30. R. Mallipeddi, and L.C. Rohan Nanoparticle-based vaginal drug delivery systems for HIV prevention Expert Opin Drug Deliv 7 1 2010 37 48
31. Q. Abdool Karim, S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, L.E. Mansoor, A.B. Kharsany, S. Sibeko, K.P. Mlisana, Z. Omar, T.N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, and D. Taylor Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science (New York, N.Y 329 (5996) 2010 1168 1174
32. J.A. Katakowski, and D. Palliser Optimizing siRNA delivery to the genital mucosa Discov Med 11 57 2006 124 132
33. O.I. Corrigan, and X. Li Quantifying drug release from PLGA nanoparticulates Eur. J. Pharm. Sci. 37 3-4 2009 477 485
34. S. Duvvuri, K. Gaurav Janoria, and A.K. Mitra Effect of polymer blending on the release of ganciclovir from PLGA microspheres Pharm. Res. 23 1 2006 215 223